Filing Flows › Rigel Pharmaceuticals (RIGL) › R&D spending
Rigel Pharmaceuticals (RIGL) R&D spending by quarter
Rigel Pharmaceuticals' R&D spending was $18.3M in Q3 2026 (third quarter 2026), +31% from Q2 2026. Over the last 7 quarters it ranged from $6.8M (Q2 2025) to $18.3M (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $18.3M | +31% | +148% |
| Q2 2026 | $14.0M | +20% | +105% |
| Q1 2026 | $11.7M | +9% | +38% |
| Q4 2025 | $10.7M | +45% | — |
| Q3 2025 | $7.4M | +8% | — |
| Q2 2025 | $6.8M | -19% | — |
| Q1 2025 | $8.4M | — | — |
Q3 2026 at a glance
Rigel Pharmaceuticals, Q3 2026: revenue $80.9M (+16% year over year), operating margin 21.1%, net earnings $13.2M, operating cash flow $34.6M. The chart follows the revenue to costs, profit and cash.
Questions
What is Rigel Pharmaceuticals' R&D spending?
Rigel Pharmaceuticals' R&D spending was $18.3M in Q3 2026 (third quarter 2026), +31% from Q2 2026.
How has Rigel Pharmaceuticals' R&D spending changed?
Over the last 7 quarters it ranged from $6.8M (Q2 2025) to $18.3M (Q3 2026).